Patent Grant
8501174
Patients undergoing treatment with certain therapeutically active agents can have certain ocular conditions as a result of that treatment. In particular, patients undergoing chemotherapy with a therapeutically active agent effective for treatment of a cancer often have ocular conditions as a result of that treatment.
One embodiment is a method comprising administering a cyclosporin, an analog or derivative thereof, or a combination thereof, to an eye of a mammal in combination with administration of a therapeutically active agent to said mammal, said therapeutically active agent being an chemotherapy agent or an antiviral agent, wherein said method is effective in preventing or treating an ocular condition associated with the use of said therapeutically active agent.
“Administration of a therapeutically active agent to said mammal” means administration of the therapeutically active agent to the mammal in any way that a therapeutically active agent may be administered. Thus, administration of the therapeutically active agent is not limited to the eye, but may include systemic administration via oral, intravenous, rectal, or other means; or administration locally to any part of the body by injection, implantation, topical administration, or other means.
Administration of the therapeutically active agent need not exactly overlap in time with the administration of the cyclosporin, an analog or derivative thereof, or a combination thereof. For example, the cyclosporin, analog or derivative thereof, or a combination thereof might be administered to a mammal before the mammal receives any of the therapeutically active agent to avoid the onset of the ocular condition. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has begun to receive the therapeutically active agent. In another example, the cyclosporin, analog or derivative thereof, or a combination thereof, might be administered after the mammal has ceased receiving the therapeutically active agent. Administration of the cyclosporin, analog or derivative thereof, or a combination thereof might also be simultaneous with the administration of the therapeutically active agent. Thus, any time relationship may exist between the mammal receiving the therapeutically active agent and the cyclosporin, analog or derivative thereof, or a combination thereof, provided that the use of the latter is reasonably related to treatment or prophylaxis of a condition associated with the former.
It may be convenient to provide a single pharmaceutical composition which comprises both (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent when the agents are to be administered simultaneously.
It may be convenient to provide (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent in form of a kit. For example, the agents may be packaged together. For example, (i) the cyclosporin, analog or derivative thereof, or a combination thereof and (ii) the therapeutically active agent may each be packaged in conventional pharmaceutical packaging such as boxes, jars, blister packs, vials, bottles, syringes etc., and the individually packaged components may then be combined to form a kit e.g. by the use of further packaging such as a box, or by joining up the individual packages. When in kit form, the agents can be taken independently of one another, thus allowing the user freedom to decide the temporal relationship between his use of each of the agents.
Use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person undergoing treatment with a therapeutically active agent for the treatment of cancer is contemplated. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of a chemotherapy agent.
Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an antiviral agent. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an antiviral agent.
Also contemplated is use of a cyclosporin, or an analog or derivative thereof, including cyclosporin A, for the treatment of ocular conditions occurring in a person who is undergoing treatment with an immunomodulator. Accordingly, a particular patient group which may benefit from the present invention is that of persons having ocular conditions resulting from the use of an immunomodulator.
Cyclosporin A is a cyclic peptide with immunosuppressive properties having the structure shown above. It is also known by other names including cyclosporine, cyclosporine A, ciclosporin, and ciclosporin A.
Other cyclosporins include cyclosporine b, cyclosporine D, cyclosporine G, which are well known in the art. Cyclosporin derivatives and analogs are also known in the art. For example, U.S. Pat. Nos. 6,254,860 and 6,350,442, incorporated by reference herein, illustrate several examples.
The ocular conditions to be prevented or treated are well known in the art. In particular, nasolacrimal stenosis, chemotherapy induced ocular toxicity, lacrimal duct stenosis, punctal stenosis, lacrimation, abnormal lacrimation, increased tearing, nasolacrimal blockage, keratitis, keratoconjunctivitis, conjunctivitis, or a combination thereof may be prevented or treated.
Also contemplated is a method comprising administering cyclosporin A topically to the eye of a person, wherein docetaxel is also administered to said person, wherein said method is effective in preventing or treating an ocular condition associated with the administration of docetaxel.
Although the ocular condition may be associated with any antiviral agent, the following antiviral agents are contemplated in particular:
Although the ocular condition may be associated with any chemotherapy agent, the following chemotherapy agents are contemplated in particular:
Derivatives of paclitaxel generally include the macrocycle shown below, where derivatives are formed at a hydroxyl moiety.
Chemotherapeutic compounds incorporating this structure are thus contemplated. For example, the structures of paclitaxel and docetaxel are shown below.
In one embodiment, the chemotherapy agent is docetaxel.
Although the ocular condition may be associated with any immunomodulator, the following immunomodulators are contemplated in particular:
While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimal duct stenosis:
While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause lacrimation:
While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause abnormal lacrimation:
While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratitis:
While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause keratoconjunctivitis:
While not intending to limit the scope of the invention in any way, the following therapeutically active agents may cause conjunctivitis:
Additionally, one or more of the ocular conditions disclosed herein may be associated with the following therapeutically active agents: abacavir sulfate, amantadine hydrochloride, amphotericin B, basiliximab, bexarotene, capecitabine, cetuximab, delavirdine mesylate, docetaxel, doxorubicin hydrochloride, enfuvirtide, epirubicin hydrochloride, erlotinib, fluorouracil, gefitinib, glatiramer acetate, imatinib mesylate, imiquimod, interferon alfa-2b, irinotecan hydrochloride, ivermectin, lamivudine, lamotrigine, leflunomide, mycophenolate mofetil, mycophenolate mofetil hydrochloride, nevirapine, oseltamivir phosphate, oxaliplatin, palivizumab, ribavirin, rimantadine hydrochloride, risedronate sodium, rituximab, saquinavir, voriconazole, zalcitabine, zidovudine, and zolpidem tartrate.
The therapeutically active agent is administered in the usual manner known in the art for the condition being treated.
Alternatively, a therapeutically active agent and cyclosporin A may be administered in a single composition.
Useful compositions are disclosed in the following patent applications, each of which is expressly incorporated by reference herein: U.S. patent application Ser. No. 11/181, 409, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 509, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 187, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 178, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/181, 428, filed on Jul. 13, 2005; U.S. patent application Ser. No. 11/255,821, filed on Oct. 19, 2005; U.S. patent application Ser. No. 11/161,218, filed on Jul. 27, 2005; and U.S. Provisional Patent Application Ser. No. 60/727,684, filed on Oct. 17, 2005.
In one embodiment, cyclosporin A is administered in the form of Restasis®, available from Allergan, Inc. The cyclosporin A is administered twice a day as indicated on the package insert.
Although there has been hereinabove described pharmaceutical compositions for the purpose of illustrating the manner in which the invention may be used to advantage, it should be appreciated that the invention is not limited thereto. Accordingly, any and all modifications, variations, or equivalent arrangements, which may occur to those skilled in the art, should be considered to be within the scope of the present invention as defined in the appended claims.
This application is a divisional of U.S. patent application Ser. No. 11/548,631, filed on Oct. 11, 2006, now issued as U.S. Pat. No. 7,745,400, which claims the benefit of priority under 35 U.S.C. §119(e) of: U.S. Provisional Patent Application No. 60/596,709, filed on Oct. 14, 2005; U.S. Provisional Patent Application No. 60/597,431, filed on Nov. 30, 2005; and U.S. Provisional Patent Application No. 60/805,577, filed on Jun. 22, 2006; all of which are expressly incorporated by reference herein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4388229 | Fu | Jun 1983 | A |
| 4388307 | Cavanak | Jun 1983 | A |
| 4649047 | Kaswan | Mar 1987 | A |
| 4814323 | Andrieu et al. | Mar 1989 | A |
| 4839342 | Kaswan | Jun 1989 | A |
| 4996193 | Hewitt et al. | Feb 1991 | A |
| 5047396 | Orban et al. | Sep 1991 | A |
| 5051402 | Kurihara et al. | Sep 1991 | A |
| 5296158 | MacGilp et al. | Mar 1994 | A |
| 5342625 | Hauer et al. | Aug 1994 | A |
| 5411952 | Kaswan | May 1995 | A |
| 5474979 | Ding et al. | Dec 1995 | A |
| 5543393 | Kim et al. | Aug 1996 | A |
| 5589455 | Woo | Dec 1996 | A |
| 5614491 | Walch et al. | Mar 1997 | A |
| 5639724 | Cavanak | Jun 1997 | A |
| 5652212 | Cavanak et al. | Jul 1997 | A |
| 5753166 | Dalton et al. | May 1998 | A |
| 5759997 | Cavanak | Jun 1998 | A |
| 5766629 | Cho et al. | Jun 1998 | A |
| 5798333 | Sherman | Aug 1998 | A |
| 5827822 | Floc'h et al. | Oct 1998 | A |
| 5827835 | Kabra | Oct 1998 | A |
| 5834017 | Cho et al. | Nov 1998 | A |
| 5891846 | Ishida et al. | Apr 1999 | A |
| 5916589 | Hauer et al. | Jun 1999 | A |
| 5951971 | Kawashima et al. | Sep 1999 | A |
| 5962014 | Hauer et al. | Oct 1999 | A |
| 5962017 | Hauer et al. | Oct 1999 | A |
| 5962019 | Cho et al. | Oct 1999 | A |
| 5977066 | Cavanak | Nov 1999 | A |
| 5977067 | Evers et al. | Nov 1999 | A |
| 6007840 | Hauer et al. | Dec 1999 | A |
| 6024978 | Hauer et al. | Feb 2000 | A |
| 6057289 | Mulye | May 2000 | A |
| 6190691 | Mak | Feb 2001 | B1 |
| 6197335 | Sherman | Mar 2001 | B1 |
| 6245805 | Broder et al. | Jun 2001 | B1 |
| 6254860 | Garst | Jul 2001 | B1 |
| 6254885 | Cho et al. | Jul 2001 | B1 |
| 6267985 | Chen et al. | Jul 2001 | B1 |
| 6284268 | Mishra et al. | Sep 2001 | B1 |
| 6294192 | Patel et al. | Sep 2001 | B1 |
| 6306825 | Cavanak | Oct 2001 | B1 |
| 6350442 | Garst | Feb 2002 | B2 |
| 6420355 | Richter et al. | Jul 2002 | B2 |
| 6468968 | Cavanak et al. | Oct 2002 | B2 |
| 6475519 | Meinzer et al. | Nov 2002 | B1 |
| 6486124 | Olbrich et al. | Nov 2002 | B2 |
| 6569463 | Patel et al. | May 2003 | B2 |
| 6582718 | Kawashima et al. | Jun 2003 | B2 |
| 6638522 | Mulye | Oct 2003 | B1 |
| 6656504 | Bosch et al. | Dec 2003 | B1 |
| 6720001 | Chen et al. | Apr 2004 | B2 |
| 6723339 | Meinzer et al. | Apr 2004 | B2 |
| 6916785 | Patel | Jul 2005 | B2 |
| 7141576 | Lackey et al. | Nov 2006 | B2 |
| 7745400 | Feinerman et al. | Jun 2010 | B2 |
| 20010003589 | Neuer et al. | Jun 2001 | A1 |
| 20010036449 | Garst | Nov 2001 | A1 |
| 20010041671 | Napoli | Nov 2001 | A1 |
| 20020012680 | Patel et al. | Jan 2002 | A1 |
| 20020013272 | Cavanak et al. | Jan 2002 | A1 |
| 20020016290 | Floc'h et al. | Feb 2002 | A1 |
| 20020016292 | Richter et al. | Feb 2002 | A1 |
| 20020025927 | Olbrich et al. | Feb 2002 | A1 |
| 20020045601 | Kawashima et al. | Apr 2002 | A1 |
| 20020107183 | Petswzulat et al. | Aug 2002 | A1 |
| 20020119190 | Meinzer et al. | Aug 2002 | A1 |
| 20020165134 | Richter et al. | Nov 2002 | A1 |
| 20030060402 | Cavanak et al. | Mar 2003 | A1 |
| 20030108626 | Benita et al. | Jun 2003 | A1 |
| 20030133984 | Ambuhl et al. | Jul 2003 | A1 |
| 20030143250 | Hauer et al. | Jul 2003 | A1 |
| 20030147954 | Yang et al. | Aug 2003 | A1 |
| 20030166517 | Fricker et al. | Sep 2003 | A1 |
| 20030211983 | Petszulat et al. | Nov 2003 | A1 |
| 20030212090 | Chen et al. | Nov 2003 | A1 |
| 20030215496 | Patel et al. | Nov 2003 | A1 |
| 20030225011 | David et al. | Dec 2003 | A1 |
| 20040048789 | Patel | Mar 2004 | A1 |
| 20040092435 | Peyman | May 2004 | A1 |
| 20040101552 | Patel | May 2004 | A1 |
| 20040102366 | Patel | May 2004 | A1 |
| 20040106546 | Napoli | Jun 2004 | A1 |
| 20040161458 | Meinzer et al. | Aug 2004 | A1 |
| 20040167063 | Cavanak et al. | Aug 2004 | A1 |
| 20040185068 | Yu et al. | Sep 2004 | A1 |
| 20040198645 | Ambuhl et al. | Oct 2004 | A1 |
| 20050013854 | Mannino et al. | Jan 2005 | A1 |
| 20050025810 | Peyman | Feb 2005 | A1 |
| 20050043258 | Bennett et al. | Feb 2005 | A1 |
| 20050048087 | Posanski | Mar 2005 | A1 |
| 20050059583 | Acheampong et al. | Mar 2005 | A1 |
| 20050085438 | Cardozo et al. | Apr 2005 | A1 |
| 20050118254 | Choi et al. | Jun 2005 | A1 |
| 20050129718 | Sherman | Jun 2005 | A1 |
| 20050147659 | Carli et al. | Jul 2005 | A1 |
| 20050196370 | Yu et al. | Sep 2005 | A1 |
| 20050272758 | Bayever et al. | Dec 2005 | A1 |
| 20100166699 | Thompson et al. | Jul 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 0146341 | Dec 1984 | EP |
| 0471293 | Feb 1992 | EP |
| 0547229 | Jun 1992 | EP |
| 956853 | May 1999 | EP |
| WO0000179 | Jan 2000 | WO |
| WO0008085 | Feb 2000 | WO |
| WO0132142 | May 2001 | WO |
| Entry |
|---|
| “Questions and Answers About Taxotere Injection Concentrate”, Patient Information Leaflet by Aventis Pharmaceuticals Inc., Rev. May 2004. |
| Pijpe et al. Rituximab Treatment in Patients With Primary Sjogren's Syndrome. Arthritis & Rheumatism. Sep. 2005, vol. 52, No. 9, pp. 2740-2750. |
| Kuwano et al., “Cyclosporine A Formulation Affects its Ocular Distribution in Rabbits”, Pharmaceutical Research, vol. 19, No. 1, Jan. 2002, 108-111. |
| Castillo, et al., “Influence of topical Cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein,” Documenta Ophthalmologica, 1995, 91, 49-55. |
| Restasis® Package Insert, (cyclosporine ophthalmic emulsion)0.05%, Sterile, Preserviatve-Free, 2 pages, (2004). |
| Uniqema, Tween™ Series. Polyoxyethylene derivatives of sorbitan esters, 2 pages, (2004). |
| RITA, Ritabate 40, INCI Nomenclature (formerly CTFA) . . . Polysorbate 40, 1 page, (1994). |
| RITA, Ritabate 60, INCI Nomenclature (formerly CTFA) . . . Polysorbate 60, 1 page. |
| RITA, Ritabate 20, INCI Nomenclature (formerly CTFA) . . . Polysorbate 20, 1 page, (1994). |
| TheMerckIndex Results-Form View, Monograph No. 07664, Titles: Polysorbates, 1 page, and Polyoxyethylene, 1 page, (2006). |
| Sandimmue® Package Insert, (cyclosporine oral solution), RxList, The Internet Drug Index, 3 pages, (2006). |
| Benitez, et al., “Influence of topical Cyclosporine A and dissolvent on corenal epithelium permeability of flurorescein,” Ophthalmologica 91: 49-55, 1995. |
| http:/thornleycompany.com/Products/PEGsters.htm, (2006). |
| www.lipochemicals.com document on Emulsifiers and Emulsifying systems (Aug. 20, 2002), pp. 1-5. |
| Schmid et al. Update on Ocular Complications of Systemic Cancer Chemotherapy. Survey of Ophthalmology, Jan.-Feb. 2006, vol. 51, No. 1, pp. 19-40. |
| Number | Date | Country | |
|---|---|---|---|
| 20100266622 A1 | Oct 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60596709 | Oct 2005 | US | |
| 60597431 | Nov 2005 | US | |
| 60805577 | Jun 2006 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11548631 | Oct 2006 | US |
| Child | 12825116 | US |
